Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11406549rdf:typepubmed:Citationlld:pubmed
pubmed-article:11406549lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0023516lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0039195lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0003316lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0030956lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C1704265lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0443288lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0079411lld:lifeskim
pubmed-article:11406549lifeskim:mentionsumls-concept:C0302891lld:lifeskim
pubmed-article:11406549pubmed:issue12lld:pubmed
pubmed-article:11406549pubmed:dateCreated2001-6-14lld:pubmed
pubmed-article:11406549pubmed:abstractTextA growing number of human tumor antigens have been described that can be recognized by CTLs in a MHC class I restricted fashion. The epithelial cell adhesion molecule (Ep-CAM) is expressed in a variety of human tumors and has attracted attention as a therapeutic target for monoclonal antibody serotherapy. We have identified immunogenic peptides derived from Ep-CAM, that bind to human leukocyte antigen-A*0201 and elicit strong peptide-specific human CTL responses, demonstrating that there is an effective T-cell repertoire against these Ep-CAM-derived peptides that can be recruited. Alterations to these peptides were made to increase their binding affinity to MHC class I molecules. The use of such "heteroclitic" peptides allowed generation of cytotoxic T cells that demonstrated increased killing of target cells pulsed not only with the heteroclitic but also with the native peptide. Most important, CTL cell lines that are generated against these peptides specifically lyse epithelial tumor cells expressing Ep-CAM but not normal hematopoietic or bronchial epithelial cells.lld:pubmed
pubmed-article:11406549pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:languageenglld:pubmed
pubmed-article:11406549pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:citationSubsetIMlld:pubmed
pubmed-article:11406549pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11406549pubmed:statusMEDLINElld:pubmed
pubmed-article:11406549pubmed:monthJunlld:pubmed
pubmed-article:11406549pubmed:issn0008-5472lld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:TrojanAAlld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:StahelR ARAlld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:GribbenJ GJGlld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:VonderheideR...lld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:SchultzeJ LJLlld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:WitzensMMlld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:HarigSSlld:pubmed
pubmed-article:11406549pubmed:authorpubmed-author:KrackhardtA...lld:pubmed
pubmed-article:11406549pubmed:issnTypePrintlld:pubmed
pubmed-article:11406549pubmed:day15lld:pubmed
pubmed-article:11406549pubmed:volume61lld:pubmed
pubmed-article:11406549pubmed:ownerNLMlld:pubmed
pubmed-article:11406549pubmed:authorsCompleteYlld:pubmed
pubmed-article:11406549pubmed:pagination4761-5lld:pubmed
pubmed-article:11406549pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:meshHeadingpubmed-meshheading:11406549...lld:pubmed
pubmed-article:11406549pubmed:year2001lld:pubmed
pubmed-article:11406549pubmed:articleTitleGeneration of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.lld:pubmed
pubmed-article:11406549pubmed:affiliationDepartment of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, 02114 Boston, Massachusetts, USA.lld:pubmed
pubmed-article:11406549pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11406549pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11406549pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11406549lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11406549lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11406549lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11406549lld:pubmed